



PRESS RELEASE

French biotech XENOTHERA accelerates its development with fundraising of 20 million euros

- XENOTHERA is developing a technological platform of exclusive "glyco-humanized" antibodies built on dual expertise in genetics and immunology.
- The financing is mainly led by the European fund EIC Fund and the Nabuboto holding company.

Nantes, June 29, 2021 - Nantes-based biotech [XENOTHERA](#) today announced that it has completed a funding round of 20 million euros. This new fundraising is financed by the current shareholders, including Didier Rousseau, founding chairman of [FAMM](#), and welcomes a round of new investors, in particular the European fund [EIC Fund](#), the Nabuboto holding company, the French fund [Anaxago Capital](#) (Objectif Innovation 18) and the group of social protection [Malakoff Humanis](#). The capital increase allows the Nantes-based company, which has gained greater recognition through the development of its anti-COVID19 treatment, XAV-19, to accelerate its growth and develop its product portfolio.

Since its creation in June 2014, XENOTHERA, which now has 17 employees, has demonstrated its agility and ability to grow rapidly. At the forefront of innovation, **the company specializing in immunology and genetic engineering is creating new therapeutic methods in many fields.** Its patented technological platform develops innovative approaches in immunotherapy by marketing glyco-humanized polyclonal antibodies (GH-pAb). These antibodies are designed to exhibit unique therapeutic properties. The XENOTHERA's platform ensures rapid development by controlling the entire process, from the choice of immunogen, selection and purification of antibodies, until it is available to patients within accelerated deadlines.

In a few years, the Nantes-based company has brought **two products to clinical stage, LIS1, an immunosuppressant in transplantation, and XAV-19, an anti-SARS-CoV-2 antibody.** In addition, it is developing XAB05, a preventive treatment for infections by multi-resistant bacteria, and a very promising portfolio in oncology.

By investing € 10 million in XENOTHERA, the [EIC Fund](#) is actively contributing to the development of a new therapeutic approach against SARS-CoV-2. The anti-COVID19 treatment, XAV-19, is based on a unique patented antibody production technology. This equity financing comes in addition to €2.16 million in grant funding through the [EIC Accelerator](#). *"We are very pleased to support this major success of XENOTHERA. The EIC Fund, with its equity investment, helped the development of XAV-19 treatment, an antibody against SARS-CoV-2. This is a key step in European fight against Covid-19"* says **Jean-David Malo, Director of the European Innovation Council and SMEs Executive Agency (EISMEA).**

“This transaction marks the confidence of our current shareholders and XENOTHERA’s attractiveness for new investors. The entry of the European EIC Fund is also a major step for our company and strengthens its international visibility. We are obviously very happy about this significant step forward, which will also allow us to strengthen our teams and structure our production on an industrial scale, with a view to the release of commercial batches, the marketing authorization (AMM) of our XAV-19 treatment, being targeted in 2022.” underlines **Odile Duvaux, president and founder of XENOTHERA.**

In total, XENOTHERA will have raised more than €43 million in dilutive and non-dilutive financing since its creation exactly 7 years ago.

About XENOTHERA:

Founded in 2014, XENOTHERA is a Nantes-based biotech that develops “glyco-humanized” polyclonal antibodies. Its technological platform is built on dual expertise in genetics and immunology. The company has a comprehensive product portfolio, the first of which, LIS1, an immunosuppressant in transplantation, has been in the clinic since 2019. XENOTHERA has also been developing its treatment for coronavirus infections for several years. XAV-19 is XENOTHERA's treatment for patients at the start of hospitalization, it is based on a unique patented antibody production technology, developed and proven for several years by biotech. XENOTHERA, member of the Atlanpole Biotherapies competitiveness cluster, is part of the scientific and medical environment of Pays de la Loire. The company has since been supported by private investors, by the Pays de la Loire region, and by BPI France.

More information: www.xenothera.com

Follow XENOTHERA on social networks: [LinkedIn](#) [Twitter](#)

About Anaxago: <https://venturecapital.anaxago.com/>

About EIC Fund:

Established in June 2020, the European Innovation Council Fund (EIC Fund) is a breakthrough initiative of the European Commission to make direct equity and quasi-equity investments (between €500.000 and €15 million) in European high impact and deep tech start-ups and scale ups. The EIC Fund provides patient capital and invests in companies from any sector, across all EU countries and countries associated to Horizon 2020. The EIC Fund aims to fill a critical financing gap and its main purpose is not to maximise financial investment returns, but to have a high impact by accompanying companies with disruptive technologies in their growth. Its objective is to crowd in market players, further sharing risks by building a large network of capital providers and strategic partners suitable for co-investments and follow on funding.

The Fund pays particular attention to empower and support female founders as well as contributing to reduce the innovation divide among EU countries.

https://eic.ec.europa.eu/investment-opportunities_en

About FAMM: <https://famm-group.com/>

About Malakoff Humanis: <https://www.malakoffhumanis.com/>

About Nabuboto: company owned by Denis Thebaud, serial entrepreneur, founder and Chairman of Innelec Multimedia, co-founder of Focus Home interactive, CEO of XANDRIE (QOBUZ).

Media relations:

IZsoGOOD

Ingrid Zémor

+ 33 6 73 729 992

xenothera@izsogood.co